Adaptive Biotechnologies (ADPT) CEO gains shares via performance awards

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp reported that CEO and Chairman Chad M. Robins acquired common stock through equity awards. On March 6, 2026, he received 709,220 shares of common stock at a price of $0.00 per share, bringing his direct holdings to 2,771,280 shares after this transaction.

On March 4, 2026, he was also awarded 127,813 shares of common stock at $0.00 per share, resulting in 2,062,060 directly held shares after that earlier transaction. A related footnote explains that these awards stem from performance share units granted on March 6, 2023 for a three-year period ending March 6, 2026, with the issuer certifying that performance goals were achieved and the units vesting on March 6, 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider ROBINS CHAD M

Role CEO and Chairman

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	709,220	$0.00	--
Grant/Award	Common Stock	127,813	$0.00	--

Holdings After Transaction: Common Stock — 2,771,280 shares (Direct)

Footnotes (1)

1. [object Object]

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/06/2026 - 07:05 PM Learn about SEC filing dates

FAQ

What does the latest Form 4 for ADPT reveal about Chad Robins’ holdings?

The Form 4 shows Chad M. Robins acquired additional Adaptive Biotechnologies (ADPT) common stock through equity awards. Following these transactions, his directly held shares increased, reflecting settlement of performance-based awards that vested after meeting long-term performance goals.

How many Adaptive Biotechnologies (ADPT) shares did Chad Robins acquire in these awards?

Chad Robins acquired 709,220 shares of Adaptive Biotechnologies common stock on March 6, 2026 and 127,813 shares on March 4, 2026. Both were recorded at a transaction price of $0.00 per share as equity award-related acquisitions.

Were the ADPT shares in this Form 4 open-market purchases or equity awards?

The reported ADPT transactions are equity award acquisitions, not open-market buys. They are coded as grants or awards at a price of $0.00 per share, reflecting stock received from company compensation programs rather than shares purchased on the public market.

What are the performance share units mentioned in the ADPT Form 4 footnote?

Each performance share unit represents a contingent right to one ADPT share. These units were granted on March 6, 2023 for a three-year period. After the issuer certified the performance goals on March 6, 2026, the performance share units vested as described.

Over what period were Adaptive Biotechnologies’ performance goals measured for these awards?

The performance share units tied to these awards covered a three-year period ending March 6, 2026. They were originally granted on March 6, 2023, and the issuer certified achievement of the specified performance goals on March 6, 2026, triggering vesting.

How did the March 2026 equity awards affect Chad Robins’ direct ADPT share ownership?

After the March 6, 2026 equity award, Chad Robins directly held 2,771,280 ADPT shares. Following the earlier March 4, 2026 award, he directly held 2,062,060 shares, reflecting stepwise increases from the vesting and settlement of performance-based awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS CHAD M

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		127,813	A	$0	2,062,060	D
Common Stock	03/06/2026		A(1)		709,220	A	$0	2,771,280	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 6, 2023, with respect to the three-year period ending on March 6, 2026. The issuer certified the achievement of the performance goals on March 6, 2026. The performance share units vested on March 6, 2026.

	/s/ Chad M Robins by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.